Back to Newsroom

Debiopharm Group™ presents advances of two key oncology clinical programs at the 26th EORTC-NCI-AACR symposium in Barcelona

Lausanne, Switzerland – November 18, 2014 – Debiopharm Group(Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs along with companion diagnostics to target unmet medical needs, announced today that new data on the investigational compounds Debio 1143 (SMAC mimetic) and Debio 1347/CH5183284 (FGFR 1,2,3 inhibitor) will be presented at the 26th European Organization for Research and Treatment of Cancer (EORTC), National Cancer Institute (NCI) and American Association for Cancer Research (AACR) (EORTC-NCI-AACR) Annual Meeting, November 18 to 21, 2014, to be held in Barcelona.

Click here to read more